When Fmoc-D-Asp-OH Replaces Side-Chain-Protected L-Asp(OtBu)-OH in a Convergent SPPS Route, Resin Loading, Coupling Stoichiometry, and Washing Solvency Need Re-optimization

In cGMP peptide API manufacturing conducted under ICH Q7 and applicable provisions of FDA 21 CFR 210–211, Fmoc-D-aspartic acid (C19H17NO6, 355.34 g/mol) introduces the D-aspartate residue without tert-butyl side-chain protection. When this monomer is substituted for Fmoc-L-Asp(OtBu)-OH in Fmoc/tBu solid-phase peptide synthesis, the coupling cycle is not directly transferable because the free β-carboxyl remains available as an acid group. This changes solubility in DCM-rich solvent systems and increases the acid-proton load interacting with tertiary amine bases. Automated batch synthesizers equipped with UV monitoring at 304 nm are used to track the dibenzofulvene-piperidine adduct during Fmoc removal. Resin substitution is typically held at 0.3–0.5 mmol/g on 2-chlorotrityl chloride or Wang resin. Coupling is performed at 20–25 °C for 45–90 min with 3–4 molar equivalents of Fmoc-D-Asp-OH relative to resin-bound free amine. The activator is held at 1:1 molar ratio to the amino acid to limit activation of the β-carboxyl through O-acylisourea or mixed anhydride side pathways; DIPEA or NMM is added at 1.8–2.5 equivalent per equivalent of activation system. Common activation cocktails are HATU/HOAt/DIPEA or DIC/Oxyma/NMM in DMF or NMP. Published direct comparative data for unprotected Fmoc-D-Asp-OH versus Fmoc-D-Asp(OtBu)-OH in automated SPPS are limited, so process development runs compare crude purity by UPLC-MS under USP <621> before locking the cycle. Fmoc removal uses 20% piperidine in DMF in two cycles of 3 min and 12 min at room temperature. Extended piperidine contact beyond 30 min total is avoided when the D-Asp unit is positioned at the C-terminus of a resin-bound dipeptide because the sequence-dependent risk of diketopiperazine formation is elevated under prolonged base exposure. After coupling, the resin is washed with DMF three times and then DCM twice to remove excess base and urea by-products before the next Fmoc removal.

A distinct downstream route uses the free β-carboxyl for side-chain anchoring to acid-labile 2-chlorotrityl chloride resin. The resin is swelled in dry DCM and treated with a pre-dissolved solution of Fmoc-D-Asp-OH and DIPEA at 0 °C to 5 °C, targeting a final loading of 0.3–0.8 mmol/g; unreacted chloride sites are capped with methanol containing 2% v/v DIPEA for 15 min. Because the β-carboxyl is attached to the solid support, the Fmoc-protected amine remains available for backbone construction, and the α-carboxyl remains free, leading after cleavage to a C-terminal D-aspartate α-carboxylic acid. This route is used for head-to-tail cyclic peptide libraries and truncated fragment synthesis where preservation of the free C-terminal carboxyl is mandatory for subsequent solution-phase lactamization. Piperidine deprotection is conducted at 20–25 °C with two cycles of 5 min and 10 min; contact with piperidine above 40 °C is avoided because the α-carbon of the resin-anchored D-aspartate unit can undergo base-catalyzed proton exchange if process control is insufficient. Cleavage from 2-chlorotrityl resin is accomplished with TFA/TIS/H2O 95:2.5:2.5 v/v/v for 1.5–2.5 h in the presence of scavenger; crude peptides are precipitated in cold diethyl ether and analyzed by RP-HPLC under USP <621>. Published production-scale data for this specific side-chain anchoring configuration are limited, but laboratory protocols consistently emphasize dry resin preparation and low-temperature loading to reduce dipeptide formation during activation.

How Is Enantiomeric Excess Measured in D-Asp Residues After Final TFA Cleavage?

Chiral identity of the D-aspartate residue after cleavage is not automatically demonstrated by parent-ion mass spectrometry because D and L epimers are isobaric. Routine release testing therefore combines acid hydrolysis with chiral derivatization. A peptide sample or the monomer itself is hydrolyzed in 6 M HCl under vacuum at 110 °C for 20–24 h; the hydrolysate is derivatized with Nα-(2,4-dinitro-5-fluorophenyl)-L-alaninamide at 40 °C for 1 h. The resulting diastereomeric derivatives are separated by reversed-phase HPLC using a C18 column and UV detection at 340 nm, following general liquid chromatography requirements in USP <621> and validation principles in ICH Q2(R1). Enantiomeric purity specifications for the finished peptide are typically set at ≥99.0% D-isomer relative to total aspartate when the D-residue is a critical stereochemical feature; monomer release certificates may additionally require specific rotation within a defined range under USP <781>. Failure to control the L-Asp impurity in Fmoc-D-Asp-OH propagates through each coupling cycle, producing a diastereomeric peptide that partially co-elutes with the target peptide on preparative C18 HPLC. Process development reports for D-Asp-containing peptide analogs indicate that exchange of D-Asp for L-Asp is detected only after chiral derivatization, not by conventional C18 analytical HPLC with UV at 215 nm. The incoming monomer therefore should be qualified with the same chiral method before use in GMP peptide campaigns.

Separate from resin-bound peptide synthesis, Fmoc-D-Asp-OH functions as a monoprotected dicarboxylic acid building block for solution-phase conjugation to amine-terminated poly(ethylene glycol) chains. The α-amine remains masked by the Fmoc group, while the β-carboxyl is available for carbodiimide-mediated amidation. Anhydrous DMF or DCM:DMF 1:1 is used, and water content is kept below 0.1% w/w by Karl Fischer titration to prevent hydrolysis of the O-acylisourea intermediate. A typical laboratory-scale ratio is Fmoc-D-Asp-OH : PEG-NH2 : EDC·HCl : HOBt : NMM = 1.2:1.0:1.3:1.3:2.0. Activation is started at 0–4 °C and allowed to warm to 20–25 °C over 12–16 h. Under these conditions the α-carboxyl adjacent to the bulky Fmoc-protected amine is less accessible, favoring β-carboxyl amidation; published quantitative selectivity data for this specific substrate are limited, and preparative HPLC or dialysis is used to remove hydrolyzed monomer and low-molecular-weight by-products. The Fmoc group is subsequently removed with 2% DBU in DMF or with 20% piperidine in DMF at room temperature; piperidine is used only when the PEG conjugate contains no residual active ester. Residual DMF, DCM, and methanol are controlled according to ICH Q3C because the resulting D-Asp-PEG intermediate is often carried into injectable peptide-polymer conjugates. The product is lyophilized to ≤0.5% w/w water before storage at −20 °C under argon.

Synthesis of D-Asp Isoform Reference Peptides for Amyloid β Diagnostic Calibrators

Analytical workflows for amyloid β field samples and aggregated synthetic β-amyloid rely on calibration peptides to distinguish spontaneous aspartate isomerization from method-based racemization. Fmoc-D-aspartic acid is incorporated into β-amyloid fragments, such as Aβ(1–16), Aβ(17–28), or full Aβ(1–42), where the native L-Asp at positions 1, 7, or 23 is replaced by D-Asp. Solid-phase synthesis on Wang resin with standard Fmoc/tBu protection is used; the D-Asp residue is coupled with HATU/DIPEA at 3 equivalent excess for 60 min at 20–25 °C. The free β-carboxyl is retained until cleavage, after which the reference peptide is purified by preparative C18 HPLC with 0.1% TFA in water and acetonitrile. Mass and sequence are confirmed by LC-MS/MS, but the D-Asp position is verified by acid hydrolysis and chiral derivatization followed by reversed-phase HPLC under USP <621>. Reference peptides are lyophilized and characterized for peptide content by amino acid analysis. The synthetic D-Asp peptide provides a retention-time reference that is unresolved by standard C18 peptide mapping alone, which makes the chiral derivatization step analytically necessary. Diagnostics developers use these peptides to verify that extraction and chromatographic methods do not generate artifactual L-to-D interconversion. Published data on lyophilized D-Asp-containing amyloid β fragments indicate storage at −20 °C with desiccant is required to reduce hydrolysis of the free β-carboxyl and to preserve peptide content for quantitative calibration.

In multi-kilogram peptide API manufacturing, the impurity profile of the incoming Fmoc-D-aspartic acid is incorporated into the supplier qualification file under ICH Q7 and ICH Q11. The monomer is not only characterized by HPLC purity and chiral purity; residual solvents from its own manufacturing process are assessed because they can carry into the peptide synthesis. A compliance matrix for solvents commonly associated with Fmoc-D-aspartic acid, peptide coupling, and lyophilization is maintained against ICH Q3C limits.

Residual piperidine is not assigned a limit in ICH Q3C and is controlled through process-specific in-house acceptance criteria using headspace GC-MS after derivatization or direct injection; contract manufacturing specifications often require not more than 0.1% w/w piperidine in lyophilized peptide APIs before release, though published limits vary by route. Elemental impurities are evaluated under ICH Q3D using a risk-based approach; for Fmoc-D-aspartic acid produced without hydrogenation or heavy-metal-catalyzed oxidation, the elemental impurity risk is generally low, but nickel, palladium, and arsenic are included in routine supplier confirmation if catalytic steps were used in the monomer synthesis. Water content is measured by Karl Fischer and controlled to ≤0.5% w/w for storage and ≤0.1% w/w when the monomer will be used in moisture-sensitive PEGylation or in mixed anhydride coupling. These controls carry direct process weight; residual water in the monomer can quench uronium activators and reduce coupling efficiency in moisture-sensitive batch syntheses. The extent is dependent on activator stoichiometry and monomer water content. The operational boundary is therefore set at: open container only under nitrogen, aliquot rapidly, and re-qualify after 30 days if the container has been stored outside a desiccated environment.